Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …

Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25
years now. The first clinical observations in patients with refractory Crohn's disease rapidly …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

This paper is the second in a series of two publications relating to the European Crohn's and
Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management …

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

Background After ileocaecal resection for Crohn's disease (CD), inflammatory lesions
frequently recur on the anastomosis and/or on the neo‐terminal ileum. Aim To identify …

Surgery for Crohn's disease (CD) is not curative, as postoperative recurrence (POR) after
ileocolonic resection is the rule in the absence of prophylactic treatment. In the present …

Background Excessive visceral adipose tissue has been associated with poorer outcomes in
patients with inflammatory bowel disease. Aim To determine whether body composition is …

Background Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after
ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early …